Citi Reiterates Buy Rating on Health Catalyst Inc. (HCAT)

June 6, 2024 10:32 AM EDT Send to a Friend
Citi analyst Daniel Grosslight reiterated a Buy rating and $9.00 price target on Health Catalyst Inc. (NASDAQ: HCAT).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login